D
Dilip K. Tosh
Researcher at National Institutes of Health
Publications - 106
Citations - 2739
Dilip K. Tosh is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Adenosine receptor & Adenosine. The author has an hindex of 28, co-authored 100 publications receiving 2203 citations. Previous affiliations of Dilip K. Tosh include Indian Institutes of Technology & Indian Institute of Technology Bombay.
Papers
More filters
Journal ArticleDOI
Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a
Tsvetan Serchov,Hans-Willi Clement,Martin K. Schwarz,Felice Iasevoli,Dilip K. Tosh,Marco Idzko,Kenneth A. Jacobson,Andrea de Bartolomeis,Claus Normann,Knut Biber,Knut Biber,Dietrich van Calker +11 more
TL;DR: Specific siRNA knockdown of homer1a in mPFC enhanced depressive-like behavior and prevented the antidepressant effects of A1R upregulation, SD, imipramine, and ketamine treatment, while viral overexpression of homer 1a in the mP FC had antidepressant effects.
Journal ArticleDOI
Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development.
TL;DR: This review focuses on key compounds as AR agonists and positive allosteric modulators (PAMs) for disease treatment or diagnosis.
Journal ArticleDOI
Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states.
Joshua W. Little,Amanda Ford,Ashley M. Symons-Liguori,Zhoumou Chen,Kali Janes,Timothy M. Doyle,Jennifer Y. Xie,Livio Luongo,Dilip K. Tosh,Sabatino Maione,Kirsty Bannister,Anthony H. Dickenson,Todd W. Vanderah,Frank Porreca,Kenneth A. Jacobson,Daniela Salvemini +15 more
TL;DR: A3AR activation by adenosine as an endogenous anti-nociceptive pathway is revealed and the development of A3AR agonists as novel therapeutics to treat chronic pain is supported.
Journal ArticleDOI
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.
Kenneth A. Jacobson,Stefania Merighi,Katia Varani,Pier Andrea Borea,Stefania Baraldi,Mojgan Aghazadeh Tabrizi,Romeo Romagnoli,Pier Giovanni Baraldi,Antonella Ciancetta,Dilip K. Tosh,Zhan-Guo Gao,Stefania Gessi +11 more
TL;DR: The outlook for development of A3AR modulators for human therapeutics is encouraging, and two prototypical selective agonists, N6‐(3‐Iodobenzyl)adenosine‐5′‐N‐methyluronamide (IB‐MECA; CF101) and 2‐chloro‐N6‐
Journal ArticleDOI
Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy
Kali Janes,Carrie Wahlman,Joshua W. Little,Timothy M. Doyle,Dilip K. Tosh,Kenneth A. Jacobson,Daniela Salvemini +6 more
TL;DR: Results suggest that inhibition of an astrocyte-associated neuroinflammatory response contributes to the protective actions of A3 AR signaling and continues to support the pharmacological basis for selective A3AR agonists as adjuncts to chemotherapeutic agents for the management of chronic pain.